The authors demonstrated that a JAK2 inhibitor (ruxolitinib) blunted the growth of cisplatin-resistant H1299 cells and enhanced antitumor activity by inhibiting tumor growth and inducing caspase-3 expression in tumor models with cisplatin resistance.44 However, further study of the efficacy and safety of combination treatments with JAK2 inhibitors is needed. This evidence concerns the gene JAK2 and neoplasm.